Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation
BackgroundChronic heart failure (CHF) is a complex cardiovascular disease caused by different pathological mechanisms. Modern medicine has made advancements in CHF treatment; however, there are still many challenges. Ershen Zhenwu Decoction (ESZWD) is a Xin'an medicine that has been clinically...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1561963/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850178779864891392 |
|---|---|
| author | Yulong Liu Yulong Liu Xinyue Wang Xinyue Wang Maomao Zhang Maomao Zhang Dan Cheng Dan Cheng Zhenpeng Zhu Lan Ge Xiaoyu Cheng |
| author_facet | Yulong Liu Yulong Liu Xinyue Wang Xinyue Wang Maomao Zhang Maomao Zhang Dan Cheng Dan Cheng Zhenpeng Zhu Lan Ge Xiaoyu Cheng |
| author_sort | Yulong Liu |
| collection | DOAJ |
| description | BackgroundChronic heart failure (CHF) is a complex cardiovascular disease caused by different pathological mechanisms. Modern medicine has made advancements in CHF treatment; however, there are still many challenges. Ershen Zhenwu Decoction (ESZWD) is a Xin'an medicine that has been clinically applied for years and had good efficacy against CHF; however, its underlying mechanisms remain undetermined. Therefore, this study aims to investigate the primary molecular mechanisms of ESZWD in CHF treatment and elucidate its multi-target and multi-level mode of action.ObjectiveThe aim of this study was to investigate the main molecular mechanisms of ESZWD for the treatment of CHF and to elucidate its multi-target and multi-level mode of action.MethodsThis study employed a network pharmacology approach to analyze the main ESZWD components and core targets. Furthermore, primary CHF targets were predicted to develop a protein–protein interaction (PPI) network and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Moreover, molecular docking was carried out to validate the binding between active ingredients and key targets. For in vitro studies, myocardial cell injury models were employed, and immunofluorescence, RT-qPCR, Western blot, and flow cytometry were carried out to validate the critical targets of relevant signaling pathways and the specific ESZWD regulatory mechanisms.ResultsNetwork pharmacology identified 437 targets for 34 major ESZWD components. Of these, 216 drug–disease intersection targets were identified. The PPI network analysis identified the following core targets: STAT3, HSP90AA1, MAPK8, NFKB1, HIF1A, MMP9, PTGS2, BCL2L1, TLR4, and ESR1. GO analysis revealed that these targets were associated with exogenous stimuli responses, phosphorylation regulation, inflammatory response, and protein tyrosine kinase activity. Furthermore, KEGG analysis showed that ESZWD predominantly impacts cancer, inflammatory response, and apoptosis pathways, with c-Jun N-terminal kinase/mitogen-activated protein kinase (JNK/MAPK)-regulated apoptosis being a key pathway. In vitro analyses revealed that ESZWD effectively inhibited JNK activation, modulated MAPK signaling, downregulated pro-apoptotic gene expression, and significantly reduced cardiomyocyte apoptosis rates, thus validating the network pharmacology findings.ConclusionOur study shows that paeoniflorin, acetylaconitine, and cryptotanshinone bind to key proteins in the JNK/MAPK apoptosis pathway. In vitro validation confirms drug serum from ESZWD regulates this pathway, supporting its therapeutic potential for CHF. |
| format | Article |
| id | doaj-art-b74f869efed44fae9cf6e7ec950d2387 |
| institution | OA Journals |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-b74f869efed44fae9cf6e7ec950d23872025-08-20T02:18:39ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-04-011210.3389/fcvm.2025.15619631561963Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validationYulong Liu0Yulong Liu1Xinyue Wang2Xinyue Wang3Maomao Zhang4Maomao Zhang5Dan Cheng6Dan Cheng7Zhenpeng Zhu8Lan Ge9Xiaoyu Cheng10First Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaXin'an Key Laboratory of Medical Science, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaXin'an Key Laboratory of Medical Science, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaXin'an Key Laboratory of Medical Science, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaXin'an Key Laboratory of Medical Science, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaFirst Affiliated Hospital of Anhui University of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, ChinaBackgroundChronic heart failure (CHF) is a complex cardiovascular disease caused by different pathological mechanisms. Modern medicine has made advancements in CHF treatment; however, there are still many challenges. Ershen Zhenwu Decoction (ESZWD) is a Xin'an medicine that has been clinically applied for years and had good efficacy against CHF; however, its underlying mechanisms remain undetermined. Therefore, this study aims to investigate the primary molecular mechanisms of ESZWD in CHF treatment and elucidate its multi-target and multi-level mode of action.ObjectiveThe aim of this study was to investigate the main molecular mechanisms of ESZWD for the treatment of CHF and to elucidate its multi-target and multi-level mode of action.MethodsThis study employed a network pharmacology approach to analyze the main ESZWD components and core targets. Furthermore, primary CHF targets were predicted to develop a protein–protein interaction (PPI) network and perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Moreover, molecular docking was carried out to validate the binding between active ingredients and key targets. For in vitro studies, myocardial cell injury models were employed, and immunofluorescence, RT-qPCR, Western blot, and flow cytometry were carried out to validate the critical targets of relevant signaling pathways and the specific ESZWD regulatory mechanisms.ResultsNetwork pharmacology identified 437 targets for 34 major ESZWD components. Of these, 216 drug–disease intersection targets were identified. The PPI network analysis identified the following core targets: STAT3, HSP90AA1, MAPK8, NFKB1, HIF1A, MMP9, PTGS2, BCL2L1, TLR4, and ESR1. GO analysis revealed that these targets were associated with exogenous stimuli responses, phosphorylation regulation, inflammatory response, and protein tyrosine kinase activity. Furthermore, KEGG analysis showed that ESZWD predominantly impacts cancer, inflammatory response, and apoptosis pathways, with c-Jun N-terminal kinase/mitogen-activated protein kinase (JNK/MAPK)-regulated apoptosis being a key pathway. In vitro analyses revealed that ESZWD effectively inhibited JNK activation, modulated MAPK signaling, downregulated pro-apoptotic gene expression, and significantly reduced cardiomyocyte apoptosis rates, thus validating the network pharmacology findings.ConclusionOur study shows that paeoniflorin, acetylaconitine, and cryptotanshinone bind to key proteins in the JNK/MAPK apoptosis pathway. In vitro validation confirms drug serum from ESZWD regulates this pathway, supporting its therapeutic potential for CHF.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1561963/fullErshen Zhenwu decoctionnetwork pharmacologymolecular dockingJNK/MAPKapoptosis |
| spellingShingle | Yulong Liu Yulong Liu Xinyue Wang Xinyue Wang Maomao Zhang Maomao Zhang Dan Cheng Dan Cheng Zhenpeng Zhu Lan Ge Xiaoyu Cheng Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation Frontiers in Cardiovascular Medicine Ershen Zhenwu decoction network pharmacology molecular docking JNK/MAPK apoptosis |
| title | Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation |
| title_full | Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation |
| title_fullStr | Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation |
| title_full_unstemmed | Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation |
| title_short | Mechanism of Ershen Zhenwu Decoction in ameliorating chronic heart failure via JNK/MAPK-regulated apoptosis: insights from network pharmacology and experimental validation |
| title_sort | mechanism of ershen zhenwu decoction in ameliorating chronic heart failure via jnk mapk regulated apoptosis insights from network pharmacology and experimental validation |
| topic | Ershen Zhenwu decoction network pharmacology molecular docking JNK/MAPK apoptosis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1561963/full |
| work_keys_str_mv | AT yulongliu mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT yulongliu mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT xinyuewang mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT xinyuewang mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT maomaozhang mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT maomaozhang mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT dancheng mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT dancheng mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT zhenpengzhu mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT lange mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation AT xiaoyucheng mechanismofershenzhenwudecoctioninamelioratingchronicheartfailureviajnkmapkregulatedapoptosisinsightsfromnetworkpharmacologyandexperimentalvalidation |